328 related articles for article (PubMed ID: 19102734)
1. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
[TBL] [Abstract][Full Text] [Related]
2. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
[TBL] [Abstract][Full Text] [Related]
3. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
6. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
Taylor D; Hanssens L; Loze JY; Pans M; L'Italien G; Marcus RN
Eur Psychiatry; 2008 Aug; 23(5):336-43. PubMed ID: 18423987
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
8. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
11. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
13. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Jeong HG; Lee MS; Lee HY; Ko YH; Han C; Joe SH
Int Clin Psychopharmacol; 2012 Jul; 27(4):177-83. PubMed ID: 22407277
[TBL] [Abstract][Full Text] [Related]
14. Switching antipsychotic medications: not enough, too often, or just right?
Weiden PJ
Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
[No Abstract] [Full Text] [Related]
15. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Chen CY; Lin TY; Wang CC; Shuai HA
Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
[TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
19. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]